These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

189 related articles for article (PubMed ID: 6421992)

  • 21. R-(-)-deprenyl as a possible protective agent in Parkinson's disease.
    Tetrud JW; Langston JW
    J Neural Transm Suppl; 1987; 25():69-79. PubMed ID: 3123606
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Long-term experience with selegiline and levodopa in Parkinson's disease.
    Lieberman A
    Neurology; 1992 Apr; 42(4 Suppl 4):32-6; discussion 41-8. PubMed ID: 1584430
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Pharmacology of MAO B inhibitors: mode of action of (-)deprenyl in Parkinson's disease.
    Youdim MB
    J Neural Transm Suppl; 1986; 22():91-105. PubMed ID: 3097263
    [TBL] [Abstract][Full Text] [Related]  

  • 24. (-)Deprenyl in the treatment of decompensated Parkinson's disease.
    Csanda E; Tárczy M; Takáts A
    J Neural Transm Suppl; 1986; 22():247-52. PubMed ID: 3097259
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Selegiline slows the progression of the symptoms of Parkinson disease.
    Pålhagen S; Heinonen E; Hägglund J; Kaugesaar T; Mäki-Ikola O; Palm R;
    Neurology; 2006 Apr; 66(8):1200-6. PubMed ID: 16540603
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [A long-term clinical effect of selegiline hydrochloride on Parkinson's disease].
    Mizuno Y; Kondo T; Takubo H; Yokochi F
    No To Shinkei; 1996 May; 48(5):467-72. PubMed ID: 8672306
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Treatment strategies for extension of levodopa effect.
    LeWitt PA
    Neurol Clin; 1992 May; 10(2):511-26. PubMed ID: 1584187
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Experience with selegiline in the treatment of Parkinson's disease.
    Poewe W; Gerstenbrand F; Ransmayr G
    J Neural Transm Suppl; 1987; 25():131-5. PubMed ID: 3123599
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Deprenyl in the management of response fluctuations in patients with Parkinson's disease on levodopa.
    Schachter M; Marsden CD; Parkes JD; Jenner P; Testa B
    J Neurol Neurosurg Psychiatry; 1980 Nov; 43(11):1016-21. PubMed ID: 6777463
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The effect of deprenyl and levodopa on the progression of Parkinson's disease.
    Olanow CW; Hauser RA; Gauger L; Malapira T; Koller W; Hubble J; Bushenbark K; Lilienfeld D; Esterlitz J
    Ann Neurol; 1995 Nov; 38(5):771-7. PubMed ID: 7486869
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Selegiline as an adjunct to conventional levodopa therapy in Parkinson's disease. Experience with this type B monoamine oxidase inhibitor in 200 patients.
    Elizan TS; Yahr MD; Moros DA; Mendoza MR; Pang S; Bodian CA
    Arch Neurol; 1989 Dec; 46(12):1280-3. PubMed ID: 2511825
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The effect of deprenyl (selegiline) on cognition and emotion in parkinsonian patients undergoing long-term levodopa treatment.
    Portin R; Rinne UK
    Acta Neurol Scand Suppl; 1983; 95():135-44. PubMed ID: 6428146
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Impact of deprenyl and tocopherol treatment on Parkinson's disease in DATATOP patients requiring levodopa. Parkinson Study Group.
    Ann Neurol; 1996 Jan; 39(1):37-45. PubMed ID: 8572664
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Deprenyl (selegiline) combined with levodopa and a decarboxylase inhibitor in the treatment of Parkinson's disease.
    Presthus J; Hajba A
    Acta Neurol Scand Suppl; 1983; 95():127-33. PubMed ID: 6428145
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Levodopa and monoamine oxidase inhibitor combination therapy. A controlled clinical trial.
    Grundmann M; Schimrigk K
    J Neural Transm Suppl; 1987; 25():115-9. PubMed ID: 3323420
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Can we differentiate symptomatic and neuroprotective effects in parkinsonism? The dopamine agonist lisuride delays the need for levodopa therapy to a similar extent as reported for deprenyl.
    Runge I; Horowski R
    J Neural Transm Park Dis Dement Sect; 1991; 3(4):273-83. PubMed ID: 1772580
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Selegiline in the treatment of Parkinson's disease--long term experience.
    Yahr MD; Elizan TS; Moros D
    Acta Neurol Scand Suppl; 1989; 126():157-61. PubMed ID: 2515721
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The pharmacological basis of the beneficial effects of (-)deprenyl (selegiline) in Parkinson's and Alzheimer's diseases.
    Knoll J
    J Neural Transm Suppl; 1993; 40():69-91. PubMed ID: 8294902
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Selegiline in the early and late phases of Parkinson's disease.
    Csanda E; Tárczy M
    J Neural Transm Suppl; 1987; 25():105-13. PubMed ID: 3123597
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Deprenyl (selegiline) in the treatment of Parkinson's disease.
    Birkmayer W
    Acta Neurol Scand Suppl; 1983; 95():103-5. PubMed ID: 6428140
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.